Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001864458 | SCV002130193 | pathogenic | not provided | 2021-08-16 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the TTPA protein in which other variant(s) (p.Leu243Trpfs*21) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with TTPA-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ile218Asnfs*2) in the TTPA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 61 amino acid(s) of the TTPA protein. |
Fulgent Genetics, |
RCV005040451 | SCV005677251 | likely pathogenic | Familial isolated deficiency of vitamin E | 2024-03-07 | criteria provided, single submitter | clinical testing |